Deregulated circRNAs in Epithelial Ovarian Cancer With Activity in Preclinical In Vivo Models: Identification of Targets and New Modalities for Therapeutic Intervention

被引:1
|
作者
Weidle, Ulrich H. [1 ,3 ]
Birzele, Fabian [2 ,4 ]
机构
[1] Roche Innovat Ctr Munich, Roche Pharm Res & Early Dev, Penzberg, Germany
[2] Roche Innovat Ctr Basel, Roche Pharm Res & Early Dev, Pharmaceut Sci, Basel, Switzerland
[3] Roche Diag GmbH, Roche Innovat Ctr Munich, Nonnenwald 2, D-82372 Penzberg, Germany
[4] Roche Innovat Ctr Basel, Roche Pharm Res & Early Dev, Pharmaceut Sci, CH-4051 Basel, Switzerland
关键词
Inhibition and reconstitution of circ RNA; small hairpin RNA (shRNA); small interfering RNA (siRNA); target validation; xenograft models; review;
D O I
10.21873/cgp.20442
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial ovarian cancer (EOC) is associated with a dismal prognosis due to development of resistance to chemotherapy and metastasis in the peritoneal cavity and distant organs. In order to identify new targets and treatment modalities we searched the literature for up- and and downregulated circRNAs with efficacy in preclinical EOC-related in vivo systems. Our search yielded circRNAs falling into the following categories: cisplatin and paclitaxel resistance, transmembrane receptors, secreted factors, transcription factors, RNA splicing and processing factors, RAS pathwayrelated components, proteolysis and cell-cycle regulation, signaling-related proteins, and circRNAs regulating proteins in additional categories. These findings can be potentially translated by validation and manipulation of the corresponding targets, inhibition of circRNAs with antisense oligonucleotides (ASO), small interfering RNAs (siRNA) or small hairpin RNA (shRNA) or by reconstituting their activity.
引用
收藏
页码:237 / 237
页数:1
相关论文
共 13 条
  • [1] CircRNAs in Pancreatic Cancer: New Tools for Target Identification and Therapeutic Intervention
    Weidle, Ulrich H.
    Nopora, Adam
    CANCER GENOMICS & PROTEOMICS, 2024, 21 (04) : 327 - 349
  • [2] Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical In Vivo Models
    Weidle, Ulrich H.
    Birzele, Fabian
    CANCER GENOMICS & PROTEOMICS, 2023, 20 (02) : 117 - 131
  • [3] In vivo dropout screens identified new drug targets for epithelial ovarian cancer
    Kodama, Michiko
    Kodama, Takahiro
    Yoshihara, Kosuke
    Hashimoto, Kae
    Mabuchi, Seiji
    Sawada, Kenjiro
    Kimura, Tadashi
    CANCER SCIENCE, 2018, 109 : 565 - 565
  • [4] Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research
    Clark, James
    Fotopoulou, Christina
    Cunnea, Paula
    Krell, Jonathan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer
    Jones, MB
    Krutzsch, H
    Shu, HJ
    Zhao, YM
    Liotta, LA
    Kohn, EC
    Petricoin, EF
    PROTEOMICS, 2002, 2 (01) : 76 - 84
  • [6] Gastric Cancer: Identification of microRNAs Inhibiting Druggable Targets and Mediating Efficacy in Preclinical In Vivo Models
    Weidle, Ulrich H.
    Birzele, Fabian
    Brinkmann, Ulrich
    Auslaender, Simon
    CANCER GENOMICS & PROTEOMICS, 2021, 18 (04) : 497 - 514
  • [7] Elevated and secreted phospolidase A2 activities as new potential therapeutic targets in human epithelial ovarian cancer
    Cai, Qingchun
    Zhao, Zhenwen
    Antalis, Caryl
    Yan, Libo
    Del Priore, Giuseppe
    Hamed, Ali Hassan
    Stehman, Frederick B.
    Schilder, Jeanne M.
    Xu, Yan
    FASEB JOURNAL, 2012, 26 (08): : 3306 - 3320
  • [8] Design, Synthesis, and Preclinical Activity in Ovarian Cancer Models of New Phosphanegold(I)-N-heterocyclic Carbene Complexes
    Sulaiman, Adam A. A.
    Casagrande, Naike
    Borghese, Cinzia
    Corona, Giuseppe
    Isab, Anvarhusein A.
    Ahmad, Saeed
    Aldinucci, Donatella
    Altaf, Muhammad
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (21) : 14424 - 14440
  • [9] PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENT DERIVED XENOGRAFTS: DEVELOPMENT AND CHARACTERIZATION OF PRECLINICAL IN VIVO MODELS FOR THE IDENTIFICATION AND TESTING OF NEW THERAPEUTIC APPROACHES
    Da Ros, A.
    Indio, V.
    Porcu, E.
    Borella, G.
    Benetton, M.
    Tregnago, C.
    Cairo, S.
    Michielotto, B.
    Bresolin, S.
    Buldini, B.
    Pession, A.
    Locatelli, F.
    Pigazzi, M.
    HAEMATOLOGICA, 2022, 107 : 20 - 21
  • [10] SOX2 Targets Fibronectin 1 to Promote Cell Migration and Invasion in Ovarian Cancer: New Molecular Leads for Therapeutic Intervention
    Lou, Xiaoyan
    Han, Xu
    Jin, Chengmeng
    Tian, Wei
    Yu, Wei
    Ding, Dong
    Cheng, Lihua
    Huang, Bingding
    Jiang, Huawei
    Lin, Biaoyang
    OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2013, 17 (10) : 510 - 518